The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Race-associated clinicogenomic predictors in non-small cell lung cancer treated with immune checkpoint inhibitors.
 
Nirosha King
No Relationships to Disclose
 
Rochelle Fayngor
No Relationships to Disclose
 
Lingzhi Hong
No Relationships to Disclose
 
Ryan Nguyen
Consulting or Advisory Role - EMD Serono; Panacea Pharmaceuticals
Speakers' Bureau - Bristol-Myers Squibb/Medarex; Daiichi Sankyo/Astra Zeneca; Merck; Pfizer
Research Funding - EMD Serono; Exelixis
Travel, Accommodations, Expenses - Merck
 
Dawen Sui
No Relationships to Disclose
 
Waree Rinsurongkawong
No Relationships to Disclose
 
Elliana Young
No Relationships to Disclose
 
J. Jack Lee
Honoraria - AstraZeneca; AstraZeneca
 
Mehmet Altan
Consulting or Advisory Role - AstraZeneca; BMS; GlaxoSmithKline; InSightec; Lyell Immunopharma; Regeneron
Speakers' Bureau - Nektar
Research Funding - Adaptimmune (Inst); BioNTech SE; Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Henlius; Jounce Therapeutics (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer; Shattuck Labs (Inst); verismo (Inst)
Travel, Accommodations, Expenses - Nektar
Other Relationship - Hengenix; Nanobiotix (Inst)
 
Bingnan Zhang
Honoraria - Dava Oncology; IDEOlogy Health
Consulting or Advisory Role - Abdera Thereapeutics; Oncohost
 
Natalie Vokes
Honoraria - Cardinal Health; Genentech; Guardant Health; HMP; Medlive; OMNI Health Media; OncLive/MJH Life Sciences; PlatformQ Health; Sanofi; Tango Therapeutics; Targeted Oncology
Consulting or Advisory Role - Amgen; AstraZeneca; Catalyst Pharmaceuticals; EMD Serono; ImmunityBio; Lilly; OncoCyte; Oncohost; Pfizer; Regeneron; Remedy Health; Sanofi; Sanofi/Regeneron; Summit pharmaceuticals; Tempus; Xencor
Research Funding - Amgen; Bristol Myers Squibb; Circulo; EMD Serono/Merck; IDEAYA Biosciences; Mirati Therapeutics; OncoCyte; Sanofi; Summit Health
Travel, Accommodations, Expenses - Regeneron
 
Xiuning Le
Consulting or Advisory Role - Abbvie; ABION; Allyst; ArriVent Biopharma; ArriVent Biopharma; AstraZeneca; Aviston; Bayer; Black Diamond Therapeutics; BlossomHill Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Lilly; EMD Serono; Hengrui Therapeutics; Janssen Oncology; Lilly; Merus; Novartis; PineTree; Regeneron; Spectrum Pharmaceuticals; Systimmune; Taiho Pharmaceutical
Research Funding - ArriVent Biopharma (Inst); Boehringer Ingelheim (Inst); EMD Serono (Inst); Janssen (Inst); Lilly (Inst); Regeneron (Inst); Teligene (Inst)
Travel, Accommodations, Expenses - EMD Serono; Johnson & Johnson/Janssen; Regeneron; Spectrum Pharmaceuticals
 
Hai Tran
Consulting or Advisory Role - ABION; Oncohost
Research Funding - Bristol Myers Squibb (Inst)
 
Haniel Araujo
Research Funding - Revolution Medicines (Inst)
 
Don Gibbons
Stock and Other Ownership Interests - Exact Sciences; Nektar
Honoraria - IDEOlogy Health
Consulting or Advisory Role - Aktis Oncology; AstraZeneca; Lilly; Menarini; Onconova Therapeutics; Sanofi
Research Funding - Astellas Pharma; AstraZeneca (Inst); Boehringer Ingelheim (Inst); Janssen; Lilly; Mirati Therapeutics (Inst); NGM Biopharmaceuticals; Ribon Therapeutics; Takeda
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; BerGenBio; Takeda
 
Ara Vaporciyan
No Relationships to Disclose
 
John Heymach
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; ALK Positive; ArriVent Biopharma; AstraZeneca; BioNtech; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals; Lilly (Inst); Mirati Therapeutics; ModeX Therapeutics; Novartis; Ottimo Pharma; Regeneron; Sanofi/Aventis; Spectrum Pharmaceuticals; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics; Spectrum Pharmaceuticals; Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations; Patents pending regarding classification of EGFR mutations; Patents pending regarding subtyping of SCLC lung cancer.
 
Jianjun Zhang
Honoraria - BeiGene; CancerNet; Geneplus; Geneplus; Hengrui Medicine; Innovent Biologics; innovent biologics; Innovent Biologics; Origimed; Roche; Roche China; Sino-USA Biomedical Platform; Suzhou Medical Association; Takeda; Varian Medical Systems; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; Capital Medical University; fortvita biologics; Geneplus; Hunan Cancer Hospital; Johnson & Johnson/Janssen; Novartis
Research Funding - Helius; Merck; Novartis; Summit Therapeutics
Travel, Accommodations, Expenses - innovent biologics; Zhejiang Cancer Hospital
 
John Lin
No Relationships to Disclose